Does the media favor NRIX or BBOT?

In the previous week, Nurix Therapeutics had 7 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 9 mentions for Nurix Therapeutics and 2 mentions for BridgeBio Oncology Therapeutics. Nurix Therapeutics' average media sentiment score of 1.41 beat BridgeBio Oncology Therapeutics' score of 1.07 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBOT or PGEN?

In the previous week, Precigen had 12 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 14 mentions for Precigen and 2 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.07 beat Precigen's score of 0.58 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precigen 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BridgeBio Oncology Therapeutics (BBOT) Competitors

$9.19 -0.07 (-0.76%)

As of 12:46 PM Eastern

Compare

BBOT vs. NRIX, VRDN, PGEN, RARE, and NKTR

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? BridgeBio Oncology Therapeutics's main competitors and comparable companies include Nurix Therapeutics (NRIX), Viridian Therapeutics (VRDN), Precigen (PGEN), Ultragenyx Pharmaceutical (RARE), and Nektar Therapeutics (NKTR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Oncology Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Nurix Therapeutics had 7 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 9 mentions for Nurix Therapeutics and 2 mentions for BridgeBio Oncology Therapeutics. Nurix Therapeutics' average media sentiment score of 1.41 beat BridgeBio Oncology Therapeutics' score of 1.07 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics currently has a consensus price target of $34.21, indicating a potential upside of 26.53%. BridgeBio Oncology Therapeutics has a consensus price target of $24.40, indicating a potential upside of 165.51%. Given BridgeBio Oncology Therapeutics' higher probable upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

Nurix Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

BridgeBio Oncology Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	76.33	-$264.46M	-$3.45	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

Summary

BridgeBio Oncology Therapeutics beats Nurix Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Viridian Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

BridgeBio Oncology Therapeutics has lower revenue, but higher earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$71.13M	38.35	-$342.60M	-$3.37	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

In the previous week, Viridian Therapeutics had 9 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 11 mentions for Viridian Therapeutics and 2 mentions for BridgeBio Oncology Therapeutics. Viridian Therapeutics' average media sentiment score of 1.08 beat BridgeBio Oncology Therapeutics' score of 1.07 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

Viridian Therapeutics presently has a consensus price target of $38.54, suggesting a potential upside of 60.04%. BridgeBio Oncology Therapeutics has a consensus price target of $24.40, suggesting a potential upside of 165.51%. Given BridgeBio Oncology Therapeutics' higher probable upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

BridgeBio Oncology Therapeutics beats Viridian Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Precigen?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Precigen	-183.98%	423.75%	84.39%

BridgeBio Oncology Therapeutics presently has a consensus price target of $24.40, suggesting a potential upside of 165.51%. Precigen has a consensus price target of $14.50, suggesting a potential upside of 96.61%. Given BridgeBio Oncology Therapeutics' higher probable upside, equities analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Precigen	$9.68M	271.62	-$250.64M	-$1.04	N/A

In the previous week, Precigen had 12 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 14 mentions for Precigen and 2 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.07 beat Precigen's score of 0.58 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precigen	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Precigen has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

Summary

Precigen beats BridgeBio Oncology Therapeutics on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

BridgeBio Oncology Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Ultragenyx Pharmaceutical	$673M	3.82	-$575M	-$5.84	N/A

BridgeBio Oncology Therapeutics currently has a consensus price target of $24.40, suggesting a potential upside of 165.51%. Ultragenyx Pharmaceutical has a consensus price target of $59.22, suggesting a potential upside of 126.95%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Ultragenyx Pharmaceutical had 25 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 27 mentions for Ultragenyx Pharmaceutical and 2 mentions for BridgeBio Oncology Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 1.11 beat BridgeBio Oncology Therapeutics' score of 1.07 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BridgeBio Oncology Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Nektar Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Nektar Therapeutics	$55.23M	46.52	-$164.08M	-$6.70	N/A

BridgeBio Oncology Therapeutics presently has a consensus target price of $24.40, suggesting a potential upside of 165.51%. Nektar Therapeutics has a consensus target price of $141.50, suggesting a potential upside of 88.02%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Nektar Therapeutics had 15 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 17 mentions for Nektar Therapeutics and 2 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.07 beat Nektar Therapeutics' score of 0.60 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

BridgeBio Oncology Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nektar Therapeutics beats BridgeBio Oncology Therapeutics on 9 of the 16 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBOT vs. The Competition

Export

Metric	BridgeBio Oncology Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$736.36M	$4.02B	$7.24B	$12.90B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	-3.33	11.55	272.49	24.28
Price / Sales	N/A	1,307.91	606.96	79.45
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	2.28	16.67	13.11	6.27
Net Income	-$134.04M	-$22.76M	$3.46B	$347.96M
7 Day Performance	1.21%	3.68%	2.13%	1.56%
1 Month Performance	5.03%	11.99%	8.29%	4.80%
1 Year Performance	N/A	58.96%	26.58%	17.12%

BridgeBio Oncology Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBOT BridgeBio Oncology Therapeutics	2.7365 of 5 stars	$9.19 -0.8%	$24.40 +165.5%	N/A	$736.36M	N/A	N/A	N/A
NRIX Nurix Therapeutics	3.4276 of 5 stars	$26.72 -1.2%	$34.21 +28.0%	+180.3%	$2.77B	$36.77M	N/A	300
VRDN Viridian Therapeutics	3.6402 of 5 stars	$24.29 -0.9%	$38.93 +60.3%	+30.0%	$2.75B	$71.13M	N/A	50	Positive News
PGEN Precigen	3.8942 of 5 stars	$7.20 -3.2%	$14.50 +101.4%	+74.2%	$2.57B	$9.68M	N/A	190	Insider Trade
RARE Ultragenyx Pharmaceutical	3.5654 of 5 stars	$25.83 +2.0%	$58.89 +128.0%	-10.6%	$2.55B	$673M	N/A	1,371	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. NRIX, VRDN, PGEN, RARE, and NKTR

How does BridgeBio Oncology Therapeutics compare to Nurix Therapeutics?

Summary

How does BridgeBio Oncology Therapeutics compare to Viridian Therapeutics?

Summary

How does BridgeBio Oncology Therapeutics compare to Precigen?

Summary

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does BridgeBio Oncology Therapeutics compare to Nektar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. NRIX, VRDN, PGEN, RARE, and NKTR

How does BridgeBio Oncology Therapeutics compare to Nurix Therapeutics?

Do insiders & institutionals believe in NRIX or BBOT?

Does the media favor NRIX or BBOT?

Do analysts recommend NRIX or BBOT?

Is NRIX or BBOT more profitable?

Which has more volatility and risk, NRIX or BBOT?

Which has stronger valuation and earnings, NRIX or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Viridian Therapeutics?

Do insiders and institutionals have more ownership in VRDN or BBOT?

Which has more volatility and risk, VRDN or BBOT?

Which has higher earnings and valuation, VRDN or BBOT?

Does the media refer more to VRDN or BBOT?

Is VRDN or BBOT more profitable?

Do analysts rate VRDN or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Precigen?

Is BBOT or PGEN more profitable?

Do analysts prefer BBOT or PGEN?

Which has stronger earnings and valuation, BBOT or PGEN?

Does the media prefer BBOT or PGEN?

Do insiders & institutionals have more ownership in BBOT or PGEN?

Which has more volatility & risk, BBOT or PGEN?

Summary

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

Which has more risk and volatility, BBOT or RARE?

Is BBOT or RARE more profitable?

Which has better valuation & earnings, BBOT or RARE?

Do analysts prefer BBOT or RARE?

Do insiders & institutionals have more ownership in BBOT or RARE?

Does the media prefer BBOT or RARE?

Summary

How does BridgeBio Oncology Therapeutics compare to Nektar Therapeutics?

Is BBOT or NKTR more profitable?

Which has higher earnings and valuation, BBOT or NKTR?

Do analysts prefer BBOT or NKTR?

Does the media refer more to BBOT or NKTR?

Which has more risk and volatility, BBOT or NKTR?

Do insiders & institutionals hold more shares of BBOT or NKTR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools